Upon receiving pathological results for breast cancer patients, clinicians have been puzzled by the heterogeneity of specimens, by the variances and discrepancies in data interpretation, especially when encountering HER2 equivocality. This evidence concerns the gene ERBB2 and breast carcinoma.